SARS-CoV-2 Mpro-IN-25, identified by its CAS number 2205006-23-9, is a small molecule inhibitor specifically designed to target the main protease (Mpro) of the SARS-CoV-2 virus, which is responsible for COVID-19. This compound plays a crucial role in antiviral research as it interferes with the viral replication process by inhibiting the protease that is essential for processing viral polyproteins into functional proteins. The characteristics of this compound include its molecular structure, which typically features functional groups that enhance its binding affinity to the active site of the protease. Additionally, it is evaluated for its potency, selectivity, and pharmacokinetic properties, which are critical for its potential therapeutic application. The development of such inhibitors is vital in the ongoing efforts to combat COVID-19, especially in the context of emerging variants and the need for effective antiviral treatments. Research continues to explore its efficacy and safety profile in clinical settings.

SARS-CoV-2 Mpro-IN-25

2205006-23-9: SARS-CoV-2 Mpro-IN-25, identified by its CAS number 2205006-23-9, is a small molecule inhibitor specifically designed to target the main protease (Mpro) of the SARS-CoV-2 virus, which is responsible for COVID-19. This compound plays a crucial role in antiviral research as it interferes with the viral replication process by inhibiting the protease that is essential for processing viral polyproteins into functional proteins. The characteristics of this compound include its molecular structure, which typically features functional groups that enhance its binding affinity to the active site of the protease. Additionally, it is evaluated for its potency, selectivity, and pharmacokinetic properties, which are critical for its potential therapeutic application. The development of such inhibitors is vital in the ongoing efforts to combat COVID-19, especially in the context of emerging variants and the need for effective antiviral treatments. Research continues to explore its efficacy and safety profile in clinical settings.

SARS-CoV-2 Mpro-IN-25 (Compound 3a) is a protease inhibitor for SARS-CoV-2, exhibiting an IC50 value of 0.26 μM. It demonstrates antiviral activity and is useful for research in the field of pneumonia.

CAS 2205006-23-9

SARS-CoV-2 Mpro-IN-25

SARS-CoV-2 Mpro-IN-25

Ref: TM-T200456